High potency active pharmaceutical ingredients (HPAPIs) are immensely effective pharmacologically active ingredients. They offer significant efficiency and need a low daily therapeutic dose due to their highly selective mode of action owing to their ability of inhibiting specific enzymes or binding specific receptors. HPAPI is at present amongst the most swiftly developing segments within the pharmaceutical industry, exhibiting an immensely high growth rate. This high growth rate is due to its application within the formulation of highly potent drugs and its ability of targeting precise disease cells.
The key growth trends reported by the market for HPAPIs are:
• HPAPIs to Emerge as Critical Components in Product Portfolios: HPAPI is a key niche segment and owing to its target release characteristics it is being used in target therapies for hormonal replacements and cancer, both high revenue segments within the industry. Furthermore, the extended application of high potency active pharmaceutical ingredients in musculoskeletal drugs, cardiovascular, and central nervous system has also led to their increasing demand.
Since the last decade, there has been an exponential rise in the number of patients having lifestyle-related diseases and cancer. This has resulted in the exponentially increasing demand for high potent products. In order to meet the rising demand, numerous top pharmaceutical multinational companies such as GSK, Roche, Merck, and Pfizer, are presently focusing on building their pipelines with novel therapeutics, particularly for the treatment of cancer.
At present, about 288 small molecule targeted therapies are available at different stages of development for treating cancer. HPAPI is predicted to emerge as a critical component in product portfolios as a prime area of focus for procurement managers and researchers in the coming five years owing to the rising focus on developing high efficacy drugs.
• Rise in Count of Approvals for Monoclonal Antibodies to Boost HPAPI Market: The pharmaceutical markets across the world have been witnessing a decline in market share owing to the rising patent expiries of key revenue generating drugs, reduced count of drugs within the pipeline of pharmaceutical multinational companies, and the increasing count of generic drug manufacturers exhibiting strong competition to pharmaceutical multinational companies in pricing. HPAIPs are highly being utilized in monoclonal antibodies (MAbs), antibody drug conjugates (ADCs), and in a number of other biologically active drugs. Hence, the rise in the count of approvals for monoclonal antibodies, antibody drug conjugates, and biologically active drugs is predicted to fuel the growth of the market for high potency active pharmaceutical ingredients.
• HPAPIs Segment, a Revenue Generator in Pharmaceutical Industry: HPAPI holds an immense potential and is a highly promising segment. The manufacturers of HPAPIs must elevate their technical as well as operational efficiency for staying ahead in the market. The segment of HPAPIs is as revenue generator within the pharmaceutical industry. The development of the biologics segment has resulted in the increasing application of HPAPIs in glaucoma, targeted releases therapies for cancer, and hormonal therapies.
Thus, these trends are poised to stimulate the growth of the market in the coming years. However, the absence of quality standards and stringent regulatory compliances in certain nations may inhibit the growth of the market in forthcoming years.
No comments:
Post a Comment